The FDA has granted orphan drug designation to a ciprofloxacin DPI being developed by Bayer HealthCare for the treatment of non-cystic fibrosis bronchiectasis, the company has announced. The dry powder formulation, based on Novartis’s PulmoSphere platform, is delivered using the T-326 (Podhaler) DPI. The product is currently in Phase 3 trials.
Bayer is also developing an amikacin DPI in partnership with Nektar. That product is also in Phase 3 development.
Read the Bayer Healthcare press release.
